Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma - Trial NCT06259721
Access comprehensive clinical trial information for NCT06259721 through Pure Global AI's free database. This Phase 2 trial is sponsored by Jiangxi Provincial Cancer Hospital and is currently Recruiting. The study focuses on Nasopharyngeal Carcinoma. Target enrollment is 22 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Jiangxi Provincial Cancer Hospital
Timeline & Enrollment
Phase 2
Feb 10, 2024
Aug 09, 2026
Primary Outcome
Objective response rate
Summary
The purpose of this study is to explore the efficacy and safety of a combination regimen of
 Anti-PD1 monoclonal antibody, nimotuzumab, and capecitabin in treating recurrent or
 metastatic nasopharyngeal carcinoma patients who have failed first-line platinum-based
 chemotherapy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06259721
Non-Device Trial